70 related articles for article (PubMed ID: 25810373)
1. Small molecule regulation of normal and leukemic stem cells.
Fares I; Rivest-Khan L; Cohen S; Sauvageau G
Curr Opin Hematol; 2015 Jul; 22(4):309-16. PubMed ID: 26049751
[TBL] [Abstract][Full Text] [Related]
2. Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005).
Ramanathan RK; McDonough SL; Kennecke HF; Iqbal S; Baranda JC; Seery TE; Lim HJ; Hezel AF; Vaccaro GM; Blanke CD
Cancer; 2015 Jul; 121(13):2193-7. PubMed ID: 25827820
[TBL] [Abstract][Full Text] [Related]
3. Platelet VEGF and serum TGF-β1 levels predict chemotherapy response in non-small cell lung cancer patients.
Fu BH; Fu ZZ; Meng W; Gu T; Sun XD; Zhang Z
Tumour Biol; 2015 Aug; 36(8):6477-83. PubMed ID: 25820820
[TBL] [Abstract][Full Text] [Related]
4. IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells.
Schinke C; Giricz O; Li W; Shastri A; Gordon S; Barreyro L; Bhagat T; Bhattacharyya S; Ramachandra N; Bartenstein M; Pellagatti A; Boultwood J; Wickrema A; Yu Y; Will B; Wei S; Steidl U; Verma A
Blood; 2015 May; 125(20):3144-52. PubMed ID: 25810490
[TBL] [Abstract][Full Text] [Related]
5. Medicinal Chemistry and NMR Driven Discovery of Novel UDP-glucuronosyltransferase 1A Inhibitors That Overcome Therapeutic Resistance in Cells.
Osborne MJ; Sulekha A; Culjkovic-Kraljacic B; Gasiorek J; Ruediger E; Jolicouer E; Marinier A; Assouline S; Borden KLB
J Mol Biol; 2024 Jan; 436(2):168378. PubMed ID: 38043731
[TBL] [Abstract][Full Text] [Related]
6. Harnessing Ferroptosis to Overcome Drug Resistance in Colorectal Cancer: Promising Therapeutic Approaches.
Cheng X; Zhao F; Ke B; Chen D; Liu F
Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958383
[TBL] [Abstract][Full Text] [Related]
7. JUNB mediates oxaliplatin resistance via the MAPK signaling pathway in gastric cancer by chromatin accessibility and transcriptomic analysis.
Li S; Wei Y; Sun X; Liu M; Zhu M; Yuan Y; Zhang J; Dong Y; Hu K; Ma S; Zhang X; Xu B; Jiang H; Gan L; Liu T
Acta Biochim Biophys Sin (Shanghai); 2023 Nov; 55(11):1784-1796. PubMed ID: 37337631
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetics of hepatocellular carcinoma and cholangiocarcinoma.
Alonso-Peña M; Sanchez-Martin A; Sanchon-Sanchez P; Soto-Muñiz M; Espinosa-Escudero R; Marin JJG
Cancer Drug Resist; 2019; 2(3):680-709. PubMed ID: 35582588
[TBL] [Abstract][Full Text] [Related]
9. Backbone assignment of the apo-form of the human C-terminal domain of UDP-glucuronosyltransferase 1A (UGT1A).
Osborne MJ; Coutinho de Oliveira L; Volpon L; Borden KLB
Biomol NMR Assign; 2018 Oct; 12(2):315-318. PubMed ID: 29934866
[TBL] [Abstract][Full Text] [Related]
10. Histone variant H3.3 orchestrates neural stem cell differentiation in the developing brain.
Xia W; Jiao J
Cell Death Differ; 2017 Sep; 24(9):1548-1563. PubMed ID: 28524856
[TBL] [Abstract][Full Text] [Related]
11. Predicting Chemotherapy Resistance in AML.
Yeung CCS; Radich J
Curr Hematol Malig Rep; 2017 Dec; 12(6):530-536. PubMed ID: 28397032
[TBL] [Abstract][Full Text] [Related]
12. When will resistance be futile?
Borden KL
Cancer Res; 2014 Dec; 74(24):7175-80. PubMed ID: 25477336
[TBL] [Abstract][Full Text] [Related]
13. The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation.
Zahreddine HA; Culjkovic-Kraljacic B; Assouline S; Gendron P; Romeo AA; Morris SJ; Cormack G; Jaquith JB; Cerchietti L; Cocolakis E; Amri A; Bergeron J; Leber B; Becker MW; Pei S; Jordan CT; Miller WH; Borden KL
Nature; 2014 Jul; 511(7507):90-3. PubMed ID: 24870236
[TBL] [Abstract][Full Text] [Related]
14. GLI1-Inducible Glucuronidation Targets a Broad Spectrum of Drugs.
Zahreddine HA; Culjkovic-Kraljacic B; Gasiorek J; Duchaine J; Borden KLB
ACS Chem Biol; 2019 Mar; 14(3):348-355. PubMed ID: 30763062
[TBL] [Abstract][Full Text] [Related]
15. Molecular targeting of the UDP-glucuronosyltransferase enzymes in high-eukaryotic translation initiation factor 4E refractory/relapsed acute myeloid leukemia patients: a randomized phase II trial of vismodegib, ribavirin with or without decitabine.
Assouline S; Gasiorek J; Bergeron J; Lambert C; Culjkovic-Kraljacic B; Cocolakis E; Zakaria C; Szlachtycz D; Yee K; Borden KLB
Haematologica; 2023 Nov; 108(11):2946-2958. PubMed ID: 36951168
[TBL] [Abstract][Full Text] [Related]
16. Emerging roles for UDP-glucuronosyltransferases in drug resistance and cancer progression.
Allain EP; Rouleau M; Lévesque E; Guillemette C
Br J Cancer; 2020 Apr; 122(9):1277-1287. PubMed ID: 32047295
[TBL] [Abstract][Full Text] [Related]
17. Molecular Pathways: GLI1-Induced Drug Glucuronidation in Resistant Cancer Cells.
Zahreddine HA; Borden KL
Clin Cancer Res; 2015 May; 21(10):2207-10. PubMed ID: 25810373
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
